Anti-HCV E2 Recombinant Antibody (e509) (CAT#: MRO-1204LC)

Figure 1 Critical residues abrogating mAb binding.

Antibodies are divided into neutralizers and non-neutralizers. Epitope residues are marked in red, while residues that are part of the CD81bs are underlined. The threshold below which a decrease in reactivity defines a residue as part of an epitope was determined for each antibody (e137 < 15%, e20 < 20%, e301 < 20%, e509 < 15%, e10 < 30%, e8 < 20%, H60 < 15%).

A Biologically-validated HCV E1E2 Heterodimer Structural Model

Figure 2 Inhibition of binding of probe FLAG-Fab antigen by previous binding of different concentrations of purified unlabeled Fabs used as competitors.

Mapping B-Cell Epitopes of Hepatitis C Virus E2 Glycoprotein Using Human Monoclonal Antibodies from Phage Display Libraries

Figure 3 Inhibition of binding of human recombinant Fabs by previous binding of a 1:20 dilution of sera obtained from HCV-infected patients and from two HCV-negative controls.

All HCV-positive sera were demonstrated to contain HCV RNA of genotype 1b and to have an ELISA titer against HCV/E2 of>1:500.